Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

Real-World Rates and Management of Thrombocytopenia Due to Cancer Treatment in Advanced/Metastatic Female Genitourinary Malignancies

Joshua F Ransom, PhD, Aaron Galaznik, MDMBA, Emelly Rusli, Bruno Lempernesse, MS, Marc Berger, MD

Blood (2019) 134 (Supplement_1): 4895.

https://doi.org/10.1182/blood-2019-129086

Published: 2019

Journal Articles

Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia

Scott M. Portwood, MBA, MS, Marianna C Cantella, BE, Tara L. Cronin, BA, Eunice S. Wang, MD

Blood (2019) 134 (Supplement_1): 1371.

https://doi.org/10.1182/blood-2019-130427

Published: 2019

Journal Articles

STAG2 Loss Gives Rise to Therapeutically Targetable DNA Damage Repair Defects and Altered Replication Fork Dynamics in Acute Myeloid Leukaemia

Harmony Estelle Black, BSc, Satpal Jhujh, Grant S Stewart, BSc, PhD, Kienan I Savage, PhD, Ken I Mills, PhD FRCPath, BSc

Blood (2019) 134 (Supplement_1): 1255.

https://doi.org/10.1182/blood-2019-129828

Published: 2019

Journal Articles

TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins

Blood (2019) 134 (Supplement_1): 1200.

https://doi.org/10.1182/blood-2019-132005

Published: 2019

Journal Articles

The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness

Geethu Emily Thomas, PhDMSc,BSc, Grace Egan, MD, Laura Garcia Prat, Boaz Nachmias, MD PhD, Jordan M Chin, Fieke W Hoff, BSc, Kerstin Kaufmann, PhD, Rose Hurren, BSc, Marcela Gronda, MSc, Neil MacLean, Xiaoming Wang, Veronique Voisin, PhD, Aaron Botham, Andrea Arruda, Mark D. Minden, MD PhD, Gary D Bader, Steven M. Kornblau, MD, John E. Dick, PhD, Aaron D Schimmer, MD PhD

Blood (2019) 134 (Supplement_1): 2532.

https://doi.org/10.1182/blood-2019-123121

Published: 2019

Journal Articles

Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 5534.

https://doi.org/10.1182/blood-2019-132001

Published: 2019

Journal Articles

PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma

Daniele Caracciolo, MD, Giada Juli, PhD, Francesca Scionti, PhD, Gaetanina Golino, PhD, Mariamena Arbitrio, MD, Emanuela Altomare, PhD, Katia Todoerti, PhD, Katia Grillone, PhD, Maria Teresa Di Martino, PhD, Marco Rossi, MD, Antonino Neri, MD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2019) 134 (Supplement_1): 3107.

https://doi.org/10.1182/blood-2019-128245

Published: 2019

Journal Articles

PARP Inhibition Sensitize BCR-ABL1 Positive Cel

Haruka Hiroki, MD, Masatoshi Takagi, MD PhD, Yuko Ishi, MD, Jinhua Piao, Tomohiro Morio, MD PhD

Blood (2019) 134 (Supplement_1): 3367.

https://doi.org/10.1182/blood-2019-127853

Published: 2019

Journal Articles

Familial Clustering of Hematological Malignancies: Harbingers of Wider Germline Cancer Susceptibility

Anna L Brown, PhD, Milena Babic, BMPharBio (Hons), Andreas Schreiber, Jinghua Feng, PhD, Julia Dobbins, BSc (Hons), Peer Arts, PhD, Paul Wang, PhD, Kerry Phillips, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Parvathy Venugopal, PhD MSc, BSc, Susan Branford, PhD FFSc (RCPA), Nicola Poplawski, MD, Christopher N Hahn, PhD, Hamish S Scott, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 3794.

https://doi.org/10.1182/blood-2019-131642

Published: 2019

Journal Articles

High Expression of BCAT1 promotes Acute Myeloid Leukemia Progression and Sensitize to PARP Inhibitor

Jie Jin, PhD, Jie Jin, PhD, Jiajia Pan, Yungui Wang, PhD, Shujuan Huang, Shihui Mao, Qing Ling, Jinghan Wang, MD PhD, Chenying Li

Blood (2019) 134 (Supplement_1): 5041.

https://doi.org/10.1182/blood-2019-125221

Published: 2019

Journal Articles

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Rana Gbyli, MS, Yuanbin Song, MD, Wei Liu, PhD, Yimeng Gao, PhD, Namrata S Chandhok, MD, Xiaoying Fu, MD, Xiaman Wang, MD PhD, Amisha Patel, MS, Ranjini Sundaram, PhD, Toma Tebaldi, PhD, Giulia Biancon, PhD, Anastasia Ardasheva, BS, Ashley Qin, Mukhtar Sadykov, MD, Padmavathi Mamillapalli, BS, Richard Flavell, PhD, Thomas Prebet, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD

Blood (2019) 134 (Supplement_1): 4222.

https://doi.org/10.1182/blood-2019-130814

Published: 2019

Journal Articles

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Cheng-Yu Tsai, PhD, Hongying Zhang, MD PhD, William G Rice, PhD, Stephen B Howell, MD

Blood (2019) 134 (Supplement_1): 5755.

https://doi.org/10.1182/blood-2019-123571

Published: 2019

Journal Articles

S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition

B. Hilda Ye, PhD, Elaine Chung, PhD, Kith Pradhan, PhD, Ana Acuna-Villaorduna, MD, Yanhua Wang, MD PhD, Aditi Shastri, MD, Advaitha Madireddy, PhD, Amit Verma, MBBS, R.Alejandro Sica, MD, Murali Janakiram, MD MS

Blood (2019) 134 (Supplement_1): 3779.

https://doi.org/10.1182/blood-2019-131364

Published: 2019

Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 3909.

https://doi.org/10.1182/blood-2019-129168

Published: 2019

Journal Articles

Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition

Laura Monaghan, BSc, Matthew Edward Massett, MSc, BSc, Roderick P Bunschoten, BSc, Petrisor Alin Pirvan, MSc, BSc, Alex Hoose, Bsc, PhD, Taeju Park, BSc, Joana Bittencourt-Silvestre, BSc, MSc, Robert M J Liskamp, BSc, PhD, Heather G Jørgensen, Xu Huang, BSc, PhD

Blood (2019) 134 (Supplement_1): 3756.

https://doi.org/10.1182/blood-2019-125355

Published: 2019

Journal Articles

DNA Methyltransferase Inhibitors Promote Homologous Recombination Deficiency through Induction of Immune Signaling, Sensitizing Acute Myeloid Leukemia Cells to PARP Inhibitors

Aksinija A Kogan, BS, MS, Lena J Mclaughlin, BS, Maria R. Baer, MD, Stephen Baylin, MD, Michael Topper, BS, Feyruz V. Rassool, BSc, PhD

Blood (2019) 134 (Supplement_1): 3763.

https://doi.org/10.1182/blood-2019-129535

Published: 2019

Journal Articles

STAG2 Mutations Alter Cohesin Ring Function and Provide Therapeutic Vulnerabilities in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 940.

https://doi.org/10.1182/blood-2018-99-117480

Published: 2018

Journal Articles

CRISPR/Cas9-Generated Models Uncover Therapeutic Vulnerabilities of Del(11q) Chronic Lymphocytic Leukemia Cells to Dual BCR and PARP Inhibition

Miguel Quijada Álamo, BSc, MSc, María Hernández-Sánchez, PhD, José Luis Ordóñez, PhD, Verónica Alonso Pérez, PhD, Ana E. Rodriguez, PhD, Ignacio García-Tuñón, PhD, Ana B Herrero, PhD, Laura San-Segundo, Michaela Gruber, MD PhD, Juan Luis García, PhD, Rocio Benito, PhD, Catherine J. Wu, MD, Jesús-María Hernández-Rivas, MD PhD

Blood (2018) 132 (Supplement 1): 948.

https://doi.org/10.1182/blood-2018-99-116080

Published: 2018

Journal Articles

An Integrated Genomics Analysis Identifies Recurrent Gain- and Loss-of-Function Events and in Distinct Subtypes of Multiple Myeloma

Sara Nasser, PhD, Jessica Aldrich, Daniel Penaherrera, BSc, Austin Christofferson, BSc, Christophe Legendre, Jennifer Yesil, MS, Daniel Auclair, PhD, Winnie Liang, PhD, Sagar Lonial, MD, Sheri Skerget, PhD, Jonathan J Keats, PhD

Blood (2018) 132 (Supplement 1): 113.

https://doi.org/10.1182/blood-2018-99-119354

Published: 2018

Journal Articles

Targeting PARP1 As an Effective Treatment for Diffuse Large B-Cell Lymphoma with High Level of γH2AX

Yanyan Liu, Peipei Zhang, Jiuyang Zhang, Wenping Zhou, Jialin Ma, Xinyang Zhao, PhD

Blood (2018) 132 (Supplement 1): 5799.

https://doi.org/10.1182/blood-2018-99-117590

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Real-World Rates and Management of Thrombocytopenia Due to Cancer Treatment in Advanced/Metastatic Female Genitourinary Malignancies

Addition of the PARP Inhibitor, Talazoparib, to Gemtuzumab Ozogamicin Significantly Enhances Anti-Leukemic Activity in Human CD33+ Acute Myeloid Leukemia

STAG2 Loss Gives Rise to Therapeutically Targetable DNA Damage Repair Defects and Altered Replication Fork Dynamics in Acute Myeloid Leukaemia

TET2 Loss Accelerates Leukemogenesis By Disrupting Mismatch Repair Proteins

The Metabolic Enzyme Hexokinase 2 Localizes to the Nucleus in AML and Normal Hematopoietic Stem/Progenitor Cells to Maintain Stemness

Integrated Multi-Level Omics to Characterize Bortezomib Resistance in Multiple Myeloma

PARP1-Mediated Alt-NHEJ Repair Is a Therapeutic Target in Multiple Myeloma

PARP Inhibition Sensitize BCR-ABL1 Positive Cel

Familial Clustering of Hematological Malignancies: Harbingers of Wider Germline Cancer Susceptibility

High Expression of BCAT1 promotes Acute Myeloid Leukemia Progression and Sensitize to PARP Inhibitor

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition

DNA Methyltransferase Inhibitors Promote Homologous Recombination Deficiency through Induction of Immune Signaling, Sensitizing Acute Myeloid Leukemia Cells to PARP Inhibitors

STAG2 Mutations Alter Cohesin Ring Function and Provide Therapeutic Vulnerabilities in Acute Myeloid Leukemia

CRISPR/Cas9-Generated Models Uncover Therapeutic Vulnerabilities of Del(11q) Chronic Lymphocytic Leukemia Cells to Dual BCR and PARP Inhibition

An Integrated Genomics Analysis Identifies Recurrent Gain- and Loss-of-Function Events and in Distinct Subtypes of Multiple Myeloma

Targeting PARP1 As an Effective Treatment for Diffuse Large B-Cell Lymphoma with High Level of γH2AX

Email alerts

ASH Publications

American Society of Hematology